U.S. markets close in 2 hours 57 minutes
  • S&P 500

    3,666.32
    -26.91 (-0.73%)
     
  • Dow 30

    29,345.04
    -245.37 (-0.83%)
     
  • Nasdaq

    10,848.14
    -19.78 (-0.18%)
     
  • Russell 2000

    1,659.18
    -20.41 (-1.22%)
     
  • Crude Oil

    77.24
    -1.50 (-1.91%)
     
  • Gold

    1,637.60
    -18.00 (-1.09%)
     
  • Silver

    18.60
    -0.31 (-1.64%)
     
  • EUR/USD

    0.9618
    -0.0070 (-0.72%)
     
  • 10-Yr Bond

    3.8590
    +0.1620 (+4.38%)
     
  • GBP/USD

    1.0678
    -0.0178 (-1.64%)
     
  • USD/JPY

    144.6030
    +1.2830 (+0.90%)
     
  • BTC-USD

    19,081.51
    +72.81 (+0.38%)
     
  • CMC Crypto 200

    438.05
    +4.95 (+1.14%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

·4 min read

[DATELINE]Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.

The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal, Bioconjugate Chemistry. Bioconjugate Chemistry is a peer-reviewed journal focused on bioconjugation and published by the American Chemical Society. The manuscript is available online and will be included in a forthcoming issue of the journal. The publication represents the final results of the previously announced collaboration between APTI and the Zeglis lab at the City University of New York to investigate APTI's site-selective conjugation in the rapidly growing field of radioimmunoconjugates (RICs). The collaboration evaluated APTI's site-selective conjugation approach using the antibody pertuzumab, an antibody that targets the HER2 receptor, which is overexpressed on many malignancies including breast and gastric cancer. In the study, APTI's conjugate was compared with conjugates prepared with two of the most common approaches to antibody conjugation - cysteine maleimide and NHS ester. The conjugates were tested in vitro for key characteristics including stability and target binding and in two in vivo models - BT-474 breast cancer (all 3 constructs) and SKOV-3 ovarian cancer (APTI and NHS ester). Key findings from the study include:

  • APTI's radioconjugate was >99% stable in human serum over 5 days

  • APTI's radioconjugate was >99% free from aggregation over 14 days

  • APTI's radioconjugate exhibited higher immunoreactivity (binding) to the HER2 receptor than the cysteine maleimide construct.

  • APTI's radioconjugate exhibited no interference with Fc receptor binding

  • In vivo - BT-474 model, PET biodistribution tumor activity concentrations at 144 h post-injection (%ID/g):

    • APTI conjugate: 126.9 ± 50.3

    • Cysteine maleimide control: 86.9 ± 53.2

    • NHS ester control: 92.5 ± 27.2

  • In vivo - SKOV-3 model, biodistribution at 144 h post-injection (%ID/g):

    • APTI conjugate: 34.5 ± 20.0

    • NHS ester control: 21.5 ± 13.4

Dr. Benjamin Krantz, President and CEO of APTI, commented, "I am thrilled by the publication of the results of our collaboration with the Zeglis lab in Bioconjugate Chemistry. Bioconjugate Chemistry is one of the most important journals in the field of bioconjugation and its publication there provides significant visibility to potential collaborators. Our results speak for themselves. We again demonstrated that our conjugation approach using simple chemistry creates highly homogeneous antibody conjugates that are rock solid stable and maintain the properties of the native antibodies. In vivo, in two challenging models, we demonstrated numerically higher tumor uptake than the comparator molecules made with the most common approaches to antibody conjugate production. It is easy to see why we are excited about our technology, this data, and the opportunities that will come as it is disseminated."

Dr. Brian Zeglis commented, "It has been wonderful working with APTI on this project. I have been impressed with APTI's highly modular and facile approach to bioconjugate production. It is the easiest approach to site-specific conjugation. The study clearly showed that APTI's radioimmunoconjugates exhibited exceptional in vitro and in vivo performance and were better-defined and more homogeneous than traditional methods. I also believe that APTI's strategy holds several key advantages over existing approaches to site-selective bioconjugation including production for the clinic. I look forward to APTI's continued development of this promising technology."

ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.

FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: 604 690-3797
http://www.advancedproteome.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134065